探花合集 Awarded Grant As Part Of Vaccine Research Consortium
Currently, 90% of existing vaccines are cold-chain dependent, and the goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
A total project fund of 鈧5.3 million has been awarded as part of Horizon 2020, the European Union research and innovation framework program, with additional funding of up to 鈧3.1 million from the Swiss State Secretariat Education, Research and Innovation (SERI) for the Swiss based consortium partners, resulting in a total project grant of 鈧8.4 million (USD8.9 million). The EU Horizon 2020 project is named MACIVIVA, which stands for 鈥淢anufacturing process for Cold-chain Independent Virosome-based Vaccines鈥. The project duration is in total 3.5 years and brings together world class expertise in the field of virosome vaccines, manufacturing, spray drying, freeze drying and analytical techniques from the pharmaceutical industry.
探花合集鈥檚 Swindon, UK facility, the manufacturing hub of its Zydis fast-dissolve formulation technology, will receive a portion of the total fund with the balance being distributed amongst the other consortium partners: Mymetics SA (Switzerland), Mymetics BV (Netherlands); Chimera Biotech Gmbh (Germany); Upperton Ltd. (UK); and Bachem AG (Switzerland).
鈥溙交ê霞 is pleased to be part of this consortium of cross-industry partners bringing innovative technologies together to address a serious global issue in the over-reliance on the cold chain with existing vaccines,鈥 commented Barry Littlejohns, 探花合集鈥檚 President of Advanced Delivery Technologies. 鈥淶ydis is the world鈥檚 best-in-class, orally disintegrating tablet technology, and we believe our experience and expertise in this area can add substantially to the project as a whole. Because of the supply chain constraints, large populations are denied access to vaccines, so we, as a group, recognize the importance and potential of this work for global vaccine development.鈥
The MACIVIVA project will receive funding from the European Union鈥檚 Horizon 2020 research and innovation program under grant agreement No 646122.
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About Zydis
探花合集鈥檚 Zydis庐 ODT fast-dissolve formulation, is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water. This may enhance the performance and may also contribute towards better patient compliance. With more than 20 products launched in 50 countries, Zydis is the world鈥檚 best in class, orally disintegrating tablet (ODT) technology. Whether to advance pharmacokinetics through pre-gastric absorption, improve patient compliance, or add marketing advantage to a valued brand, 探花合集鈥檚 customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product鈥檚 potential.
About 探花合集
探花合集 is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 90 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 探花合集 employs approximately 8,500 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. 探花合集 is headquartered in Somerset, N.J. For more information, visit www.catalent.com